158 related articles for article (PubMed ID: 37871576)
1. Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
Leavitt AD; Konkle BA; Stine KC; Visweshwar N; Harrington TJ; Giermasz A; Arkin S; Fang A; Plonski F; Yver A; Ganne F; Agathon D; Resa MLA; Tseng LJ; Di Russo G; Cockroft BM; Cao L; Rupon J
Blood; 2024 Feb; 143(9):796-806. PubMed ID: 37871576
[TBL] [Abstract][Full Text] [Related]
2. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
[TBL] [Abstract][Full Text] [Related]
3. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
[TBL] [Abstract][Full Text] [Related]
4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
[TBL] [Abstract][Full Text] [Related]
5. FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats.
Lövgren KM; Larsen MS; Zintner SM; Small JC; Kjelgaard-Hansen M; Häger M; Petersen M; Wiinberg B; Margaritis P
J Thromb Haemost; 2020 Jul; 18(7):1586-1597. PubMed ID: 32196903
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
[TBL] [Abstract][Full Text] [Related]
8. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
George LA; Monahan PE; Eyster ME; Sullivan SK; Ragni MV; Croteau SE; Rasko JEJ; Recht M; Samelson-Jones BJ; MacDougall A; Jaworski K; Noble R; Curran M; Kuranda K; Mingozzi F; Chang T; Reape KZ; Anguela XM; High KA
N Engl J Med; 2021 Nov; 385(21):1961-1973. PubMed ID: 34788507
[TBL] [Abstract][Full Text] [Related]
9. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment.
Symington E; Rangarajan S; Lester W; Madan B; Pierce GF; Raheja P; Robinson TM; Osmond D; Russell CB; Vettermann C; Agarwal SK; Li M; Wong WY; Laffan M
Haemophilia; 2024 Mar; 30(2):320-330. PubMed ID: 38317480
[TBL] [Abstract][Full Text] [Related]
11. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
[TBL] [Abstract][Full Text] [Related]
12. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
[TBL] [Abstract][Full Text] [Related]
14. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
[TBL] [Abstract][Full Text] [Related]
16. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
[TBL] [Abstract][Full Text] [Related]
17. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.
Rosen S; Tiefenbacher S; Robinson M; Huang M; Srimani J; Mackenzie D; Christianson T; Pasi KJ; Rangarajan S; Symington E; Giermasz A; Pierce GF; Kim B; Zoog SJ; Vettermann C
Blood; 2020 Nov; 136(22):2524-2534. PubMed ID: 32915950
[TBL] [Abstract][Full Text] [Related]
18. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
19. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
[TBL] [Abstract][Full Text] [Related]
20. The Arrival of Gene Therapy for Patients with Hemophilia A.
Castaman G; Di Minno G; De Cristofaro R; Peyvandi F
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]